Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders -- Focus on Progressive Ataxia

Report Code: PHM123A

Publish Date: Oct 2012

Publisher: BCC Publishing

Category: Pharmaceuticals

Customize This Report

Single User License: $2685

Member Price: FREE

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

  • The global market for treatments for syndromes of progressive ataxia and weakness disorders was valued at nearly $14 billion in 2011 and should reach nearly $15 billion in 2012. Total market value is expected to reach nearly $23.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.4%.
  • Progressive ataxia treatments are expected to have a value of $356.4 million in 2012 and $620.7 million in 2017, a CAGR of 11.7%.
  • Treatments for Machado-Joseph disease should total $158.4 million in 2012 and $273.5 million in 2017, a CAGR of 11.5%.

INTRODUCTION

STUDY OBJECTIVES

BCC’s goal in conducting this study is to provide an overview of the current and future characteristics of the global market for treatments of neurodegenerative (i.e., progressive ataxia and weakness) disorders.  The key objective is to present a comprehensive analysis and the future direction of treatments for these disorders as the market efforts toward drug and therapy development evolve. 

This report explores present and future strategies within the progressive ataxia and weakness disorders market, which includes treatments and therapies for dysfunctions, including progressive ataxia and progressive weakness disorder syndromes.  The market’s improvisation, setbacks and needs are also discussed.  The comparisons, usage, advantages and disadvantages of different types of technologies, including small-molecule and monoclonal antibodies, are also presented. 

A detailed analysis of the industry structure has been conducted.  Revenues are broken down by the neurodegenerative dysfunction.  Sales figures are estimated for the five-year period from 2012 through 2017. 

The report discusses applications for neurodegenerative disorder treatment and therapy technologies, with emphasis on small-molecule and monoclonal antibodies technology.  The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THIS STUDY

Extensive research in the field of progressive ataxia and weakness disorders as well as collaborations with research institutes have highlighted the importance of understanding the nature of these disorders.  New technology development is providing modifying therapies for the late stages of these disorders.  Collaborations among research institutes and pharmaceutical companies are becoming more common, as state-of-the-art technology is being explored to develop more-efficient products and therapies.

R&D spending, increasing competition, patent expiries and new technologies are shifting the market in a new direction.  The market’s overall revenue has increased from 2009 to 2011, and it continues to show growth, as new advancements, product launches and collaborations will have positive influences for the foreseeable future.  This study looks at most of the systems affected by these factors. 

Acquisition strategies and company collaborations are also covered in this report.  This study discusses the strength and weaknesses of each technology in light of the new developments, growing competition and changing customer needs.

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

This study contributes to the areas of market growth in Friedreich’s ataxia, Gerstmann-Straussler-Scheinker disease, Machado-Joseph disease, amyotrophic lateral sclerosis, progressive bulbar palsy, hereditary spastic paraplegia, hereditary neuropathies and multiple sclerosis.  Pharmaceutical biotechnical companies, research institutes and physicians will find this study of interest. 

SCOPE OF THE STUDY

The scope of this study encompasses the neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets.  BCC analyzes each market and its applications, the regulatory environments, and the technologies involved, as well as market projections and market shares.  Technological issues include the latest trends and developments.  The emerging market for enzyme inhibitors includes such countries as India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study.  BCC conducted a comprehensive literature search, which included technical newsletters and journals, among other sources.  Data were collected through interviews and correspondence with technical experts at companies that manufacture enzyme inhibitors.  Projections were based on estimates that were calculated such using information as the current number of end users, potential end users, mergers and acquisitions, and market trends.

INFORMATION SOURCES

Many companies within the industry were surveyed to obtain data for this study.  These included manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease-sector industries.  Data were gathered from various industry sources.  BCC spoke with officials within the industry and also reviewed newsletters, company literature and product literature, as well as a host of technical articles, journals, indices and abstracts.  Exhaustive investigations of databases by key terminology were completed.  In addition, data were compiled from current financial, trade and government sources.

BCC ON-LINE SERVICES

BCC Research offers an online information retrieval service.  Its home page, located at www.bccresearch.com, enables readers to:

  • Examine the complete BCC Research catalog of market research reports and place direct orders.
  • Subscribe to any of BCC Research’s many industry newsletters.
  • Read announcements of recently published reports and newly launched newsletters.
  • Register for its well-known conferences.
  • Request additional information on any BCC research product.
  • Take advantage of special offers.

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature.  This information does not constitute managerial, legal or accounting advice, nor should it serve as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is of a speculative in nature.  The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW

Analyst Credentials

Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.

Let us assist you! Our analysts are ready to tailor this report to your specific need. REACH OUT TO US TODAY

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders -- Focus on Progressive Ataxia124Free
Chapter- 1: INTRODUCTION3Free
Chapter- 2: EXECUTIVE SUMMARY2Free
Chapter- 3: OVERVIEW6Free
Chapter- 4: REGULATORY ASPECTS4Free
Chapter- 5: NEW DEVELOPMENTS9Free
Chapter- 6: GLOBAL MARKETS13Free
Chapter- 7: PROGRESSIVE ATAXIA SYNDROME MARKET27Free
Chapter- 8: PATENT ANALYSIS13Free
Chapter- 9: CURRENT SITUATION6Free
Chapter- 10: C. CRAMER & CO. GMBH38Free
Chapter- 11: APPENDIX I: ABBREVIATIONS3Free

Related Reports

Global Markets for Enzyme Inhibitors

Published - Jun 2012 | Publisher - Shalini Shahani Dewan | Code - BIO057B

The global market for enzyme inhibitors was valued at $104.4 billion in 2010 and reached nearly $104.6 billion in 2011. This market is expected to rise at a compound annual growth rate (CAGR) of 4% and reach nearly $127.4 billion by 2016.

Liver Disease Treatments: The Global Market

Published - Jan 2012 | Publisher - Shalini Shahani Dewan | Code - PHM057B

In 2009, the global market for drugs used to treat liver disease was worth approximately $12.4 billion. Sales in 2010 decreased and the market did not see much progress, causing overall global sales to remain stagnant at $12.4 billion. Estimated sales in 2011 a projected $12 billion (excluding protease inhibitors).  The market is expected to rise at a CAGR of 3.3% and reach nearly $14.2 billion by 2016.

Enzymes in Industrial Applications: Global Markets

Published - Jan 2011 | Publisher - Shalini Shahani Dewan | Code - BIO030F

The global market for industrial enzymes is estimated at $3.3 billion in 2010. This market is expected to reach $4.4 billion by 2015, a compound annual growth rate (CAGR) of 6% over the 5-year forecast period.

Recent Reports

Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets

Published - Apr 2024 | Publisher - BCC Publishing | Code - PHM046D

The global market for gastrointestinal (GI) therapeutics and diagnostics is expected to grow from $86.0 billion in 2023 and projected to reach $122.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2023 to 2028.

Global Markets and Technologies for Advanced Drug Delivery Systems

Published - Mar 2024 | Publisher - BCC Publishing | Code - PHM006N

The global market for advanced drug delivery systems is expected to increase from $262.6 billion in 2023 to $359.1 billion by the end of 2028, with a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2023-2028.

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

Published - Feb 2024 | Publisher - BCC Publishing | Code - PHM113C

The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.

Global Markets for Vaccine Technologies

Published - Feb 2024 | Publisher - BCC Publishing | Code - PHM014K

The global market for vaccine technologies is expected to grow from $45.0 billion in 2023 to $65.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.8% from 2023 to 2028.

Chagas Disease: American trypanosomiasis Market

Published - Feb 2024 | Publisher - BCC Publishing | Code - PHM282A

The report provides detailed coverage of the Chagas Disease market. It analyzes the market trends and epidemiology of CD, and the regional markets of CD. It highlights the current market for CD and gives a detailed analysis of the competitive environment. The report depicts the complete scenario of Chagas Disease, types of parasites that cause human African trypanosomiasis (HAT) and its presence in various regions of the world.

Top Trending Reports

Global Market for Cell and Gene Therapy

Published - Apr 2024 | Publisher - BCC Publishing | Code - BIO225B

The global market for cell and gene therapy is expected to grow from $7.2 billion in 2023 and projected to reach $23.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 26.4% during the forecast period of 2023 to 2028. 

Peptide Synthesis: Global Markets

Published - May 2024 | Publisher - BCC Publishing | Code - BIO252A

The global market for peptide synthesis is expected to grow from $90.1 billion in 2023 and projected to reach $157.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.8% during the forecast period of 2023 to 2028.

3D Cell Cultures: Technologies and Global Markets

Published - Mar 2024 | Publisher - BCC Publishing | Code - BIO140D

The global market for 3D cell culture is estimated to increase from $4.6 billion in 2023 to reach $14.8 billion by 2028, at a compound annual growth rate (CAGR) of 26.5% from 2023 through 2028.

Medical Magnetic Resonance Imaging (MRI): Technologies and Global Markets

Published - May 2024 | Publisher - BCC Publishing | Code - HLC078F

The global market for medical magnetic resonance imaging (MRI) is expected to grow from $7.2 billion in 2023 and projected to reach $9.8 billion by the end of 2028, at a compound annual growth rate (CAGR) of 6.4% during the forecast period of 2023 to 2028.

Oligonucleotides: Global Markets

Published - Apr 2024 | Publisher - BCC Publishing | Code - BIO220B

The global market for oligonucleotides is expected to grow from $7.0 billion in 2023 and projected to reach $11.7 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.0% during the forecast period of 2023 to 2028.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders -- Focus on Progressive Ataxia
Customize Report